Request Sample

Global Conjugate Vaccine Market

March 16, 2018

Global Conjugate Vaccine Market, By Product Type (Monovalent Conjugate Vaccines and Multivalent Conjugate Vaccines), By Disease Indication (Pneumococcal, Influenza, Diphtheria Tetanus and Pertussis (DTP) Meningococcal, Tetanus, and Others), By Patient Stage (Pediatrics and Adults), By Pathogen Type (Bacterial, Viral, and Combination (Viral and Bacterial), By Region (North America, Latin America, Europe, Asia-Pacific, and Middle East and Africa), - Global Forecast, 2020-2025.

Report Code :FMR345      
Industry : Biotechnology
Pages :200 Pages
Format :   PPT Format   PDF Format

The global conjugate vaccine market was valued at US4 xx million in 2019. This market is estimated to be valued at US$ xx million in the year 2020, and it is expected to reach US$ xx million by the year 2025, with an estimated CAGR of xx% during the forecast period   (2020−2025). Conjugate vaccines are formed by covalently bonding of a weak antigen to the strong antigen. This vaccine boost the hosts’ immunological response. The major growth drivers of the global conjugate vaccine market are advancements in the vaccine formulation, initiatives taken by the government, and prevention of major infectious diseases, such as meningitis and others. Furthermore, growing investments by the market players in research & development, increasing focus on immunization programs, and rising demand for vaccination are expected to boost the growth of the market over the forecast period. Increasing the prevalence of infectious diseases in children and a rising count of awareness programs for the promotion of vaccination will drive the growth of this market during the forecast period.

Table 1. Global Conjugate Vaccine Market Synopsis

Parameters

Description

Market Value (US$ Mn) for the Period

2018-2025

Base Year

2019

Forecast Period

2020-2025

Market Segmentation (By Product Type)

Monovalent Conjugate Vaccines and Multivalent Conjugate Vaccines

Market Segmentation (By Disease Indication)

Pneumococcal, Influenza, Diphtheria Tetanus and Pertussis (DTP)

Meningococcal, Tetanus, and Others

Market Segmentation (By Patient Stage)

Pediatrics and Adults

Market Segmentation (By Pathogen Type)

Bacterial, Viral, and Combination (Viral and Bacterial)

Regions Covered

North America, Latin America, Europe, Asia-Pacific, and Middle East and Africa

Key Players Coverage

Novartis AG, Neuron Biotech, Serum Institute of India, Pfizer, Inc., Sanofi Pasteur, Bharat Biotech, Biological E, GlaxoSmithKline, plc., Merck and Company, GlaxoSmithKline plc. Merck & Co., Inc., Fablife, SutroVax Inc., Sanofi Pasteur SA., Pfizer, Sinovac Biotech Ltd., IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Taj Pharmaceuticals Limited, Bavarian Nordic, and CSL Limited.

Key Insights

  • Latest Updates
  • Analyst Views
  • Future Outlook of the Market

Market Dynamics

The rising use of conjugate vaccines for adults and the growing count of regulatory approvals for conjugate vaccines are the factors driving growth of the global conjugate vaccine market. In July 2016, Pfizer received U.S. Food and Drug Administration (FDA) approval for Prevnar 13 – a Pneumococcal 13-valent conjugate vaccine in adults age 18 through 49. In January 2013, Pfizer received U.S. Food and Drug Administration (FDA) approval for the use of Prevnar 13 vaccine in children and adolescents aged 6 years through 17 years for the prevention of invasive pneumococcal disease. The rising prevalence of infectious diseases and the growing awareness toward the prevention of infectious diseases are anticipated to boost the global conjugate vaccine market growth during the forecast period. Although, the accessibility of the new conjugate vaccines in low-income countries are low, which is expected to restrain the global conjugate vaccine market.

Figure 1. PORTER’S Analysis

Note: The above figure is shown for illustrative purposes only, the actual data may vary and will be incorporated in the report.

North America is expected to be the most attractive market for the conjugate vaccine during the review period, due to a rise in demand for meningococcal, pneumococcal vaccines, and other conjugate vaccines. Since 2017, an epidemic of hepatitis A among adults has been occurring in a number of the U.S. cities resulting in increased demand for vaccine.

The market in the Asia Pacific is projected to show the highest growth during the forecast period attributed to rising immunization initiatives by organizations, such as The Global Alliance for Vaccines and Immunizations (GAVI) and World Health Organization (WHO), in emerging economies, such as India and China. Growing healthcare expenditure in various countries is also likely to boost the demand for the conjugate vaccines market. In 2016, the healthcare expenditure of the U.S. was US$ 8,047 per capita, which increased to US$ 10,209 per capita during the year 2017. As per WHO, in 2018, around 86% of infants worldwide received three doses of DTP-3 that protect against diphtheria-tetanus-pertussis. Thus, such initiatives by the government are expected to propel the market growth.

Figure 2. Regional Analysis

 

Note: The above figure shown for illustrative purposes only, the actual data may vary and will be incorporated in the report.

Competitive Landscape

Key players in the global conjugate vaccine market include Novartis AG, Serum Institute of India, Pfizer, Inc., Bharat Biotech, Biological E, GlaxoSmithKline, plc., Sanofi Pasteur, Neuron Biotech, Merck & Co., Inc., Fablife, SutroVax Inc., Sinovac Biotech Ltd., IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Taj Pharmaceuticals Limited, Bavarian Nordic,and CSL Limited, among others. Key development strategies of the market players are new product launches, mergers, and acquisitions. For instance, in November 2018, the state government of Haryana launched a specially designed pneumococcal conjugate vaccine to safeguard the children from pneumonia.

Telangana Health Minister C. Laxma Reddy launched a tab with custom-made software ANMOL (ANM Online) that enables us to keep all their data online. The main aim was to provide a cost-effective vaccine for children suffering from pneumonia. In September 2018, the first public-sector typhoid conjugate vaccine campaign was launched by Navi Mumbai Municipal Corporation (NMMC). The main aim was to vaccinate around 320,000 children between the ages of 9 months to 15 years. The NMMC received 100,000 doses from the Bharat Biotech International Limited. This campaign was done in two phases, and its main motive was to reduce the burden of typhoid.

Figure 3. Market Share of Key Players, 2019

 

Note: The above figure shown for illustrative purposes only, the actual data may vary and will be incorporated in the report.

By Vaccine Type

  • Monovalent Conjugate Vaccines
  • Multivalent Conjugate Vaccines

By Disease Indication

  • Pneumococcal
  • Influenza
  • Diphtheria Tetanus and Pertussis (DTP)
  • Meningococcal
  • Thyroid
  • Others

By Pathogen Type

  • Bacterial
  • Viral
  • Combination (Viral and Bacterial)

By Patient Stage

  • Pediatrics
  • Adults

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
rm
Kindly fill the below form and we will contact you within 24 hours
I have read and accept Privacy Policy

Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Note: This report provides an in-depth analysis of the global conjugate vaccine market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2025), considering 2019, as the base year.

  • What are the trends adopted by key players in the global conjugate vaccine market?
  • What key factors are expected to increase the demand for conjugate vaccine market during the forecast period 2020-2025?
  • What are the major challenges inhibiting the growth of the global conjugate vaccine market?
  • What is the total market value (US$ Mn) generated in the global conjugate vaccine market by vaccine type in 2019, and what are the forecasts by 2025?
  • Which disease indication is expected to dominate the global conjugate vaccine market in the coming years?
  • Which pathogen type contributes highest CAGR (%) in the conjugate vaccine market?
  • Which patient stage is expected to foster the conjugate vaccine market growth?
  • What was the total revenue generated by the global conjugate vaccine market across different regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa) in 2019, along with CAGR (%) for the period (2020-2025)?
  • Who are the key players contributing to the growth of the global conjugate vaccine market, and what are the new strategies adopted by them to retain a market share in the industry?
  • What is the competitive strength of the key players in the global conjugate vaccine market?
  • What are the major outcomes derived from Porter’s five forces?
  • What are the new products which are going to be approved or launched in the upcoming years, which may have a huge impact on the market?
  • What insights are derived through the analysis of key players on the following parameters: company overview, financial performance, product portfolio, geographical presence, key highlights, and strategies?

Latest Reports

Global Recombinant DNA Technology Market

Global Recombinant DNA Technology Market, By Product Type (Recombinant Protein Drugs (Insulin, Human Growth Hormone, Erythropoietin, Interferon, Blood Factors, …

Read More

Global Inactivated Vaccine Market

Global Inactivated Vaccine Market, By Product Type (Viral, Bacterial), By Inactivation method (Radiation Method, pH Concentration, Heat Inactivation, Solvent …

Read More

Middle East and Africa Epigenetics Market

Middle East and Africa Epigenetics Market, By Product type (Consumables, Enzymes, Kits & Reagents, and Instruments), By Application (Oncology, …

Read More

Global Tissue Plasminogen Activator (TPA) Market

Global Tissue Plasminogen Activator (TPA) Market, By Dosage (2mg, 50mg, and 100mg), By Administration Route (Intravenous and Regional Intra-Arterial), …

Read More

Global Biobanks Market

Global Biobanks Market, By Biological samples (DNA or RNA, Plasma, Tissue samples, Stem cells, Amniotic fluid, Cerebrospinal fluid, Blood, …

Read More

Global Vector Control Market

Global Vector Control Market, By Product Type (Insects, Rodents, and Others), Methods of control (Chemical Methods (Pyrethroids (Permethrin, Deltamethrin, …

Read More

Global Medical Drone Market

Global Medical Drone Market, By Type (Fixed Wing, Rotary Drone, and Hybrid Drones), By Application (Search and Rescue (Disaster, …

Read More

Global Agricultural Biotechnological Market

Global Agricultural Biotechnological Market, By Product Type (Plants (Conventional Techniques, Established Genetic Modification, New Breeding Techniques), Animals (Conventional Techniques, …

Read More
Validation error occured. Please enter the fields and submit it again.